Patrick Daly

DocwireNews

Patients with obstructive sleep apnea (OSA) can develop excessive daytime sleepiness (EDS). Pharmacologic agents are used to promote wakefulness in this population; however, according to a study in Annals of Internal Medicine, the effectiveness of these agents has not been directly compared. Lead author Tyler Pitre, MD, MA, and colleagues performed a systematic review and network meta-analysis to compare pharmacologic agents for EDS in OSA.After analysis, the researchers reported that solriamfetol, armodafinil-modafinil, and pitolisant-H3-autoreceptor blockers effectively reduced <a href="https://docwirenews.com/post/oxygen-resaturation-rate-a-new-marker-for-excessive-sleepiness">daytime sleepiness</a> in patients with OSA already on conventional therapies, with solriamfetol likely being the most effective.In addition, the authors noted that adverse events (AEs) likely increased the risk of discontinuation with armodafinil-modafinil and possibly increased the risk with solriamfetol.<h3>Solriamfetol, Armodafinil-Modafinil, or Pitolisant</h3>The network meta-analysis included 14 trials published to the Medline, Central, Embase, and ClinicalTrials.gov databases by November 2022. The pooled cohort consisted of 3085 patients with EDS-associated OSA who were on or eligible for conventional therapy and assigned to any pharmacological treatment.Compared with placebo at week 4, authors found Epworth Sleepiness Scale scores were probably improved by:<ul>
<li>Solriamfetol (mean difference [MD], &ndash;3.85; 95% CI, &ndash;5.24 to &ndash;2.50; high certainty)</li>
<li>Armodafinil-modafinil (MD, &ndash;2.25; 95% CI, &ndash;2.85 to &ndash;1.64; moderate certainty)</li>
<li>Pitolisant-H3-autoreceptor blockers (MD, &ndash;2.78; 95% CI, &ndash;4.03 to &ndash;1.51; moderate certainty)</li>
</ul>Compared with placebo at week 4, mean maintenance of wakefulness test (MWT) scores were also improved with high certainty by both <a href="https://medlineplus.gov/druginfo/meds/a619040.html" target="_blank" rel="noopener">solriamfetol</a> (standardized MD [SMD], 0.9; 95% CI, 0.64-1.17) and armodafinil-modafinil (SMD, 0.41; 95% CI, 0.27-0.55), whereas pitolisant-H3-autoreceptor blockers probably did not improve MWT (moderate certainty).Researchers found that AEs increased risk for discontinuation with moderate certainty for armodafinil-modafinil (relative risk [RR], 2.01; 95% CI, 1.14-3.51) and with low certainty for solriamfetol (RR, 2.07; 95% CI, 0.67-6.25). The lower degree of certainty led authors to suggest these 2 treatments may not increase the risk for serious AEs.In closing, the study&rsquo;s authors noted their findings were limited by the lack of data on long-term efficacy or efficacy among patients who had mixed or nonadherence to conventional treatments for OSA.Ultimately, the authors concluded that all 3 agents effectively reduced daytime sleepiness in patients, with solriamfetol likely being the optimal choice.Find More Research and Interviews on <a href="https://docwirenews.com/page/sleep-disorders">Sleep Disorders and Neurology</a>

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Comparing Treatments for Excessive Daytime Sleepiness in OSA

Sleep Disorders

Solriamfetol appeared to be the most effective pharmacologic agent for excessive daytime sleepiness in patients with OSA on conventional therapies.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe